Weight lost is the easiest thing to measure about a GLP-1 drug. It may also be the least useful. That is the argument being put forward by Dr Shashank R. Joshi, Consultant in the Department of Endocrinology at Sir H. N. Reliance Foundation Hospital, as GLP-1 therapies move out of specialist diabetes clinics and into the mainstream of Indian obesity care.
His point is not that these medicines underperform. It is that a falling number on a weighing scale can hide muscle loss, poor nutrition and a treatment plan that quietly collapses a year later.
The Scale Says Success. The Body May Say Otherwise
GLP-1 receptor agonists — the class that includes widely used diabetes and weight-management medicines — work by mimicking a gut hormone that slows digestion, increases fullness and improves glucose-dependent insulin release.
That biology produces visible, rapid weight change, which is precisely why it dominates the conversation. Dr Joshi's contention is that this visibility has distorted how success itself is judged.
In his framing, weight reduction is an outcome, not a definition. A patient who loses kilograms but loses strength, bone density or adherence along the way has not been treated well — they have been treated partially.
Why One Template Will Not Fit Indian Patients
India's obesity problem does not look like the obesity problem these drugs were first studied in. Body composition, dietary patterns and baseline muscle mass vary widely across regions, incomes and communities.
Protein intake is a recurring concern in Indian diets, particularly in largely vegetarian households and among older adults who need muscle-preserving nutrition most.
A protocol designed around the scale alone can push a patient toward eating less of everything — including the protein and micronutrients that protect lean tissue. Dr Joshi's argument is that the prescription and the plate have to be planned together.
Muscle, Bone and the Nutrition Bill Nobody Budgets For
Rapid weight loss of any kind — through medication, surgery or severe calorie restriction — can involve loss of lean mass alongside fat. Clinicians have long flagged this as a structural risk in obesity treatment, not a side effect of one particular drug.
Bone health adds a second layer. Nutritional deficiencies, sudden dietary change and reduced physical load all interact in ways that a five-minute prescribing consultation is unlikely to catch.
This is why the components Dr Joshi lists — nutritional assessment, body composition monitoring, strength training and medical supervision — read less like add-ons and more like the treatment itself.
Who Is Actually Affected
The people in this conversation are not abstract. They include patients with type 2 diabetes for whom GLP-1 therapy is a legitimate, guideline-supported option, and adults with obesity who have struggled with conventional approaches for years.
They also include a newer, less well-defined group: people seeking these medicines primarily for cosmetic weight loss, sometimes without a full clinical assessment.
For all three groups, the same question applies. Is anyone tracking what is being lost along with the weight?
What the Endocrine Community Is Asking For
Dr Joshi's position, as set out in the original account, is that Indian patients need tailored treatment protocols rather than a single imported template.
That means treating GLP-1 therapy as a supervised programme with defined checkpoints — a nutrition plan, periodic body composition review, resistance training, and clinical follow-up for adherence and side effects — instead of a standalone injection.
It is a professional and clinical argument, not a regulatory one. No new official guidance or directive has been reported alongside it.
The Gap Between a Prescription and a Protocol
There is a practical reason this argument matters more in India than the clinical literature might suggest: capacity.
Comprehensive obesity care requires dietitians, body composition tools and follow-up time. Much of India's outpatient care runs on short consultations and out-of-pocket spending, which makes the "support plan" the first thing to disappear.
The result is a familiar pattern — a prescription is issued, enthusiasm is high, and the nutritional and muscle-preserving work that would make the treatment durable never happens.
Dr Joshi's intervention is essentially a warning about that gap.
Confirmed Facts vs What Is Still Unclear
Confirmed: Dr Shashank R. Joshi, Consultant, Department of Endocrinology, Sir H. N. Reliance Foundation Hospital, has argued that weight loss alone cannot define GLP-1 therapy success, and that Indian care should combine nutritional assessment, body composition monitoring, strength training and medical supervision.
Confirmed: The concerns under discussion include nutritional deficiencies, muscle loss, bone health and long-term adherence.
Unclear: Whether any Indian medical body is drafting formal protocol changes, and how quickly such guidance could reach routine practice.
Unclear: How many patients in India are currently on GLP-1 therapy with structured body-composition follow-up. No verified national figure has been presented here, and none should be assumed.
The Risks — and the Case for These Drugs
Any balanced reading has to acknowledge that GLP-1 receptor agonists are not a fad. They are established therapies for type 2 diabetes, and major trials have demonstrated benefits that extend beyond blood sugar control.
For many patients, they are genuinely transformative. The critique is about how they are used, not whether they work.
The risks worth naming: unsupervised use, rapid weight loss without nutritional support, muscle and bone consequences, gastrointestinal side effects affecting adherence, and cost-driven stopping and restarting without clinical advice.
There is also a quieter risk — that the dramatic weight-loss narrative crowds out the slower, less photogenic work of diet, strength and follow-up that determines long-term outcomes.
Obesity Care Is Moving From Kilograms to Body Composition
India's debate is not happening in isolation. Globally, obesity medicine is shifting toward quality-of-weight-loss measures: preserving lean mass, protecting function, and tracking metabolic health rather than a single figure.
That shift has produced a new vocabulary in clinics — sarcopenic obesity, protein targets, resistance training prescriptions — and it is now reaching Indian endocrinology.
Dr Joshi's argument sits squarely inside this trend. It treats the weighing scale as a starting point for a conversation, not the final sentence of a report.
If You Are on a GLP-1, or Thinking About It
Do not start, stop or adjust these medicines on your own, or on the basis of what worked for someone else. They require a prescription and clinical supervision, particularly for people with existing digestive, kidney or thyroid concerns.
Ask your doctor three practical questions: What is my protein and nutrition plan? How will we track muscle and not just weight? And what happens if I stop?
Ask for a follow-up schedule, not just a prescription. If strength training is not part of the plan, ask why.
What to Watch Next
The test of this argument will be whether Indian prescribing practice starts recording body composition and nutritional status alongside weight — and whether clinics have the time and staff to do it.
Watch for hospital-led protocols, dietitian-integrated obesity programmes and professional-body commentary on GLP-1 follow-up standards. None of these has been confirmed yet.
Until then, the practical reality for patients remains uneven, and depends heavily on where and with whom they are being treated.
Our Take
The most important sentence in this debate is also the least dramatic: weight loss is a marker, not a mission.
India is adopting a powerful class of medicines faster than it is building the support system around them. Dr Joshi's contribution is to name that imbalance early, from inside clinical practice, before shortcuts harden into habits.
The measure of success will not be how many Indians lose weight on GLP-1 therapy. It will be how many keep their strength, their nutrition and their treatment intact two years later.
Frequently Asked Questions
What are GLP-1 therapies and how do they work?
GLP-1 therapies are medicines that mimic the glucagon-like peptide-1 hormone, which the gut releases after eating. They slow stomach emptying, increase feelings of fullness and improve insulin release in a glucose-dependent way, which is why they are used in type 2 diabetes and obesity treatment. In India, they must be prescribed and monitored by a qualified doctor.
Why is weight loss alone not enough to judge success?
Because weight change does not distinguish between fat and lean tissue. A patient can lose kilograms while also losing muscle, running into nutritional gaps or weakening bone health. Dr Shashank Joshi's argument is that success should be measured through nutritional status, body composition and sustained adherence, not a single number on a scale.
What should a well-structured GLP-1 treatment plan in India include?
Based on the approach Dr Joshi has outlined, it should combine a nutritional assessment, periodic body composition monitoring, strength or resistance training, and continued medical supervision. The prescription is one component of the plan, not the whole of it.
Can I take a GLP-1 medicine on my own for weight loss?
No. These are prescription medicines that require clinical assessment, dose titration and follow-up. Self-medication or buying without supervision raises the risk of side effects, nutritional problems and poorly monitored muscle and bone loss. Speak to a qualified doctor before starting, changing or stopping treatment.